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For coronary artery disease with unprotected left main stem (LMS) stenosis, coronary artery bypass grafting
(CABG) is traditionally regarded as the “standard of care” because of its well-documented and durable survival
advantage. There is now an increasing trend to use drug-eluting stents for LMS stenosis rather than CABG de-
spite very little high-quality data to inform clinical practice. We herein: 1) evaluate the current evidence in sup-
port of the use of percutaneous revascularization for unprotected LMS; 2) assess the underlying justification for
randomized controlled trials of stenting versus surgery for unprotected LMS; and 3) examine the optimum ap-
proach to informed consent. We conclude that CABG should indeed remain the preferred revascularization treat-
ment in good surgical candidates with unprotected LMS stenosis. (J Am Coll Cardiol 2008;51:885–92) © 2008
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.067s
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wercutaneous coronary intervention (PCI) is frequently
avored as an initial treatment strategy by some interven-
ional cardiologists in patients with multivessel coronary
rtery disease (CAD) despite evidence from a meta-analysis
f randomized trials (1) and registry data (2) favoring
oronary artery bypass grafting (CABG). Food and Drug
dministration approval of drug-eluting stents (DES) in
003 has further encouraged this practice even in “off-label”
ituations (3). Although DES do not improve survival or
educe myocardial infarction in comparison with bare-metal
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ccepted September 7, 2007.tents (BMS) (4), and despite concerns about their lack of
ost-effectiveness (5) and increased risk of stent thrombosis
6), enthusiasm for their use in the coronary arteries has now
ncouraged some to advocate their use in left main stem
LMS) stenosis, for which CABG is traditionally regarded
s the standard of care because of its well-documented and
urable survival advantage (7–9). Indeed, current American
ollege of Cardiology/American Heart Association (ACC/
HA) guidelines state that for LMS stenosis PCI is a class
II indication (i.e., that the procedure is generally not effective
nd may even be harmful) in those who are otherwise eligible
or CABG (10,11), and this view is echoed in the European
ociety of Cardiology’s PCI guidelines, which state that
stenting for unprotected left main disease should only be
onsidered in the absence of other revascularization options”
12). Nevertheless, in a 2004 survey of interventions for LMS
tenosis, PCI was used in 29% of European and 18% of U.S.
atients (13). This practice has been justified on the short-term
ollow-up of small cohorts of highly selected patients receiving
ES for LMS stenosis and has persuaded some intervention-
lists to question whether it is now actually time for DES to
eplace CABG completely (14).
Although there is an important role for PCI in patients
ith LMS stenosis who are hemodynamically unstable
r ineligible for CABG, this article reviews current
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Stenting Versus Surgery for LM Stem Stenosis March 4, 2008:885–92outcomes with percutaneous and
surgical revascularization to ex-
amine whether there is sufficient
clinical evidence to support the
use of stents in the majority of
elective patients with unpro-
tected LMS (i.e., where there are
no existing bypass grafts).
Pathology of LMS
and Implications for
Revascularization With
Stents or Surgery
A significant LMS stenosis is
considered to be a lesion occupy-
ing over 50% of the vessel diam-
eter. Left main stem stenosis cur-
rently occurs in 4% to 6% of all
patients undergoing coronary an-
giography (15) and in 30% of
CABG patients (16).
Left main stem stenosis is theoretically an attractive
arget for PCI because it is the most proximal component of
he left coronary circulation and because of its relatively
arge diameter. However, in reality, 3 important anatomical
eatures carry important qualifications about the likely
uccess of PCI and CABG in LMS stenosis:
Left main stem stenosis occurs as an isolated lesion in
only 6% to 9% of patients, whereas over 70% to 80% of
patients also have multivessel CAD (17–24), thereby
potentially enabling more complete coronary revascular-
ization with CABG than with stenting.
Most LMS stenoses (40% to 94%) occur in the distal
segment of the artery and extend into the proximal
coronary arteries (17–24); such bifurcated or trifurcated
lesions have a high risk of restenosis (25), while acute
occlusion at this site can have catastrophic consequences.
Morphologically, around one-half of LMS lesions have
significant calcification (15).
Whereas considerations about the precise anatomical loca-
ion and complexity of LMS stenosis impact critically on both
he short- and long-term outcomes of PCI, they have negli-
ible influence on the success of CABG, as the distal anasto-
oses of the bypass grafts are to the mid or distal coronary
asculature, well beyond all diseased segments in both the LM
nd the proximal coronary arteries, thereby protecting entire
roximal zones of vulnerable myocardium.
ationale for CABG as the “Standard
f Care” Treatment for LMS Stenosis
n 1975 Cohen and Gorlin (26) first reported that CABG
esulted in a significant improvement in 10-year survival
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
DES  drug-eluting stent(s)
IMA  internal mammary
artery
LMS  left main stem
MACE  major adverse
coronary events
PCI  percutaneous
coronary intervention
RCT  randomized
controlled trialompared with medical therapy in patients with significant dMS stenosis, an observation confirmed in 3 randomized
rials (7) and numerous observational studies over the next 2
ecades. Although both the medical therapy and surgical
echniques used in these studies are outdated by today’s
tandards (e.g., aspirin, statins, and internal mammary
rtery [IMA] grafts were not widely used), a meta-analysis
f these trials demonstrated a significant relative risk reduc-
ion in mortality with CABG of about 66% at 5 years with
he benefit extending to 10 years (7). Even so, the trials
robably substantially underestimated the real survival ben-
fit of CABG surgery because the trial patients were
elatively low risk, only 10% of surgical patients received an
MA graft (which leads to superior long-term graft patency
nd a clear survival benefit), and analysis on an intention-
o-treat basis “discounted” the survival advantage of CABG
n the 40% of the medical group who crossed over to surgery
7). Indeed, in the largest prospective study of LMS
tenosis, in which 1,484 patients in the CASS (Coronary
rtery Surgery Study) registry were followed for up to 16
ears, the overall median survival for CABG patients was
3.3 years versus 6.6 years for medical therapy (8). Since
hese pivotal studies, improvements in medical therapy have
enefited both surgical and medical groups, but in view of
he overall survival advantage of CABG in most angio-
raphic and clinical subsets, current ACC/AHA guidelines
tate that “the benefit of surgery over medical treatment in
atients with significant LMS stenosis (greater than 50%) is
ittle argued” (9).
urrent Results for CABG in LMS Stenosis
n the last decade, 6 groups from Europe and the U.S. have
eported CABG results in cohorts of at least 300 patients
ith LMS stenosis (16,27–31) (Table 1). Cumulatively,
hese studies included almost 11,000 patients of whom
round one-third (range 5% to 57%) underwent urgent
urgery with an average in-hospital mortality of 2.8% and
0-day mortality of 3% to 4.2% (Table 1). In the largest
ndividual study, the Society of Cardiothoracic Surgery in
he U.K. reported a mortality of 3% for all 5,003 patients
ndergoing CABG for LMS stenosis in 2003 (compared
ith 2% in over 17,000 patients with no LMS stenosis)
31). Two recent British studies reported excellent 2-year
urvival rates of 94% and 95% (28,30). As for all cardiac
urgical procedures, the mortality rate is strongly influenced
y comorbidities; for example, Ellis et al. (27) reported that
-year mortality for CABG in LMS stenosis varied from
% in low-risk patients to 40% in those with significant and
ultiple comorbidities (27).
Left main stem stenosis may also be particularly suitable
or the use of bilateral IMA grafts. The angiographic
atency of both IMA placed to left-sided coronary vessels is
ver 95% at 1 week and at 7 years (32) and may translate
nto a significant survival benefit. In a systematic review of
ver 15,000 CABG patients matched for age, gender,
iabetes, and left ventricular function, the hazard ratio for
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March 4, 2008:885–92 Stenting Versus Surgery for LM Stem Stenosiseath was 0.81 (95% confidence interval 0.70 to 0.94) with
ilateral versus single IMA grafts (number needed to treat,
3 to 16) (32). In addition, the use of bilateral IMA grafts
ppears safe; the ART (Arterial Revascularisation Trial)
tudy of bilateral versus single IMA grafts reported an
verall 30-day mortality of 1% in over 3,000 patients (33).
CI With BMS for LMS
nitial attempts at PCI using simple balloon angioplasty in
MS stenosis were soon abandoned because of a high rate
f procedural complications from elastic recoil and vessel
issection (Table 2). However, the ability of BMS to
inimize these complications encouraged at least 8 studies
f BMS in LMS stenosis in over 1,100 patients between
999 to 2003 (34–41). Interpretation of outcome is, how-
ver, hampered by the absence of data regarding: 1) the
ctual proportion of all LMS stenosis patients undergoing
CI rather than CABG who were ineligible for CABG
ecause of other significant comorbidity (therefore at high
isk for PCI) and/or nonsurgical preference; and 2) the
umber of patients with significant distal LMS stenosis and
ultivessel CAD.
Notwithstanding these limitations, as shown in Table 2,
he overall in-hospital mortality averaged 6% with further
mmediate revascularization in 4% (range 0% to 20%). Most
orrying, however, was a 1- to 2-year mortality of 17%
urrent Results of CABG for LMS Stenosis
Table 1 Current Results of CABG for LMS Stenosis
Author (Ref. #) (Year) Year of Surgery n
Jonsson et al. (31) (2006) 1970 to 1999 1,8
Lu et al. (30) (2006) (2005) 1997 to 2003 1,1
Keogh and Kinsman (16) (2003) 2003 5,0
Dewey et al. (29) (2006) (2001) 1998 to 1999 7
Yeatman et al. (28) (2006) (2001) 1996 to 2000 3
Ellis et al. (27) (2006) (1998) 1990 to 1995 1,5
Weighted average — 10,7
ABG  coronary artery bypass grafting; LMS  left main stem.
ight Studies of PCI Using BMS in LMS
Table 2 Eight Studies of PCI Using BMS in LMS
Author (Ref. #) Sites n % Eligible Ste
Keeley et al. (34) 1 54 — 100
Silvestri et al. (35): high risk 1 47 — 100
Silvestri et al. (35): low risk 1 93 — 100
Tan et al. (36): all 25 279 — 85
Tan et al. (36): low risk 25 89 — 85
Black et al. (37) 1 92 — 100
Takagi et al. (38) 1 63 — 58
Park et al. (39) 4 270 — 100
Brueren et al. (40) 1 71 — 64
Kelley et al. (41) 3 97 — 100
Weighted average 38 1,155MS  bare-metal stent; LMS  left main stem; PCI  percutaneous coronary angioplasty.range 3% to 31%) and a repeat revascularization rate of 29%
range 15% to 34%). However, several authors have also
eported more favorable results in “low-risk” patients
younger patients, normal ventricular function, and pre-
ominantly ostial or midshaft lesions) with 1-year mortality
ates of 3.4% (in the Ultima registry) (36) to 7% (35) and a
-year mortality of 7.4% (39). Even in these patients,
owever, repeat revascularization rates were 28% to 32%.
urthermore, the results of CABG would also be excellent
n such low-risk populations; for example, the 1-year mor-
ality rate in the 504 CABG patients in the SoS (Stent or
urgery) trial was 0.8% (42).
Indeed, the overall high late mortality and revasculariza-
ion rates with BMS influenced the 2001 (10) and 2005 (11)
CC/AHA guidelines to state that PCI was a class III
ndication for virtually all LMS stenosis in those who are
therwise eligible for CABG (11) and the European Society
f Cardiology guidelines to conclude that “stenting for
nprotected left main disease should only be considered in
he absence of other revascularization options” (12).
CI With DES for LMS Stenosis
lthough, in comparison with BMS, DES do not reduce
he risk of death or myocardial infarction in stable CAD
4,6), their ability to reduce restenosis has encouraged their
se in LMS disease (Table 3). Although 7 different groups
Mortality (%)
Hospital 30-Day 1-Year 2-Year
2.7 — — —
2.8 3 5 6
3 — — —
— 4.2 — —
2.4 — — 5
2.3 — — —
2.8 — — —
In-Hospital to 30-Day 1- to 2-Year Follow-Up
Mortality Revascularization Mortality Revascularization
5% 20% 31% 15%
9% — 11% 15%
0% — 3% 21%
14% — 24% 34%
3.4% — 3.4% 31%
4% — 6.5% 16%
0% 10% 16% 31%
0% 4% 7% 29%
1% 4% 10% 25%
9% — 28% 20%
6% 3% 17% 29%88
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Stenting Versus Surgery for LM Stem Stenosis March 4, 2008:885–92ave published results involving 599 patients between 2004
o 2006 (17–24), interpretation is limited by small individ-
al patient numbers (50 to 130 per study), incomplete
ngiographic assessment of restenosis (only 1 study reas-
esses all patients [20]), short duration of follow-up (mean
f 11 months), and lack of a control group in 4 studies
thereby inviting interpretive biases). Furthermore, with the
xception of the Bologna registry (24), for studies of BMS
here is little data regarding what proportions of all LMS
tenosis patients underwent PCI rather than CABG or were
neligible for CABG because of other comorbidity and/or
onsurgical preference (and were, therefore, also at high risk
or PCI).
As shown in Table 3, considering that 42% to 94% of
atients had significant distal or bifurcation LMS stenosis and
7% to 100% also had significant CAD, the immediate results
re encouraging. The in-hospital mortality rate averaged 2.4%
range 0% to 11%), the immediate repeat revascularization rate
as 2% (range 0% to 6%), and biochemical evidence of
yocardial infarction was 6% (range 0% to 9%). However, at a
ean follow-up of 11 months (range 6 to 18 months),
ortality had increased to 7% (range 0% to 14%) and repeat
evascularization to 13% (range from 2% to 38%).
One group has reported no deaths in 116 LMS patients
t 18 months of follow-up but restenosis in 13% of the 85%
f patients who underwent angiography at 6 months
18,22). In contrast, in the only study with complete
ngiographic follow-up, the rate of restenosis increased
rom 34% at 3 months to 44% at 9 months (20). This
isparity in restenosis rates may not only reflect differences
n patient selection, interventional techniques, and com-
leteness and timing of angiographic follow-up but, most
mportantly, differences in the incidence of distal/
ifurcation LMS stenosis. The crucial importance of distal
MS stenosis as a predictor of adverse outcomes has
ecently been re-emphasized by Valgimigli et al. (25) who,
t a median of 18 months, reported a 3-fold increase in
ajor adverse coronary events (MACE) in distal LMS
tenosis (30%) compared with those without (11%). And
oth Price et al. (20) and Palmerini et al. (24) warned that
s restenosis was frequently asymptomatic, it mandated
erial angiographic follow-up, a view reiterated by Baim et
l. (14) who cautioned, “Without that safety net, one would
xpect an up-tick in late mortality events resulting from
nrecognized restenosis in this critical location” (14).
learly, such a strategy not only has significant cost impli-
ations but also still begs the question: in view of potential
ate failure of DES, how long should such surveillance
ngiography be continued?
In contrast, the use of DES in nonbifurcation (an
nfrequent anatomical subset), unprotected LMS appears to
e safe and effective based on a recent multicenter retro-
pective registry of 147 patients that reported a restenosis
ate of 1% at 6-month angiographic follow-up, a major
dverse clinical event rate of 7.4%, and a cumulative cardiacmortality of 2.7% at a median follow-up of 886 days (43).T
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March 4, 2008:885–92 Stenting Versus Surgery for LM Stem Stenosisurrent Comparisons of
CI and CABG for LMS Stenosis
o date only 1 randomized trial of PCI versus CABG has
een reported (44). The LEMANS (Study of Unprotected
eft Main Stenting Versus Bypass Surgery) trial was a
andomized trial of 52 PCI (35% with DES) and 53 CABG
atients of whom approximately 60% had distal LMS
tenosis, and of whom 75% of the CABG group and 60% of
he PCI group had 3-vessel coronary artery disease (p 
.08). Although, as expected, the CABG group had more
hort-term complications within the first month after sur-
ery, the primary outcome of MACE at 1 year was similar
n the 2 groups, as 15% of the PCI group required further
CI or CABG. Furthermore, the fact that only 72% of the
ABG group received an internal mammary artery graft
espite its well established survival benefit raises questions
bout the quality of the surgery in the LEMANS trial, as
se of this graft should approach 100% in contemporary
ractice. Currently a larger randomized trial of DES versus
ABG for LMS stenosis (the SYNTAX [Synergy between
CI and Taxus and Cardiac Surgery] trial) has now com-
leted enrollment.
Only 2 groups have reported registry data in patients with
MS stenosis undergoing CABG or PCI with DES (21,24)
ith at least 1-year follow-up. In the Bologna registry of
11 patients with LMS stenosis, 68% were deemed suitable
or either PCI or CABG, 19% for CABG only, and 13% for
CI only (24). At a median follow-up of 14 months, the
ortality was 12% in 154 CABG and 13% in 157 PCI
atients (but 3%, respectively, in low-risk patients). The
epeat revascularization rate was, respectively, 3% for
ABG and 26% for PCI. In an Italian registry of 249 LMS
atients, there was no difference in 1-year mortality after
djustment for baseline characteristics in the 107 PCI and
42 CABG patients, who were significantly older (68 vs. 64
ears) with a higher proportion of renal failure (8% vs. 2%)
21). Again, however, repeat revascularization was 20% in
CI versus 4% of CABG patients, probably reflecting the
act that 87% of patients had bifurcation disease (21).
The lack of long term follow-up is a fundamental
imitation of all of these studies. The benefits of CABG
urgery compared with medical therapy emerges beyond 1
ear, as perioperative mortality and morbidity in the CABG
roup becomes offset by mortality from CAD in the medical
roup. Hence, the apparent lack of difference at 1 year is not
eassuring and does not contradict the longer-term benefits
f CABG.
tent Thrombosis With DES
f restenosis is the Achilles heel of BMS, then stent
hrombosis is a potentially important limitation of DES,
ith impaired endothelialization and healing the most
mportant of several possible mechanisms (45). However,
hereas restenosis usually has a relatively benign clinical flutcome (except possibly in the LMS), stent thrombosis is
ssociated with a 65% to 70% increased risk of myocardial
nfarction and a mortality of 25% to 45% (6). This persistent
otentially prothrombotic substrate necessitates prolonged
ual antiplatelet medication with aspirin and clopidogrel for
t least a year (46), compared with 1 month with BMS.
The precise incidence of DES thrombosis is unknown. It
as initially reported to be around 0.5%, similar to BMS, in
he pre-approval pivotal trials of BMS versus DES (in
ow-risk patient and lesion cohorts, which involved limited
ollow-up of 9 to 12 months). A recent Food and Drug
dministration Circulatory Devices Panel concluded that
ES now account for around 80% of all stent use and that
early 60% of their use is in “off-label” situations where,
epending on the complexity of the patient and the lesion,
hey were “associated with increased risks of both early and
ate stent thrombosis, as well as death or myocardial
nfarction” with an annual thrombosis risk estimated at
etween 1% to 5% (3).
The ACC/AHA now recommend that a longer duration
f dual antiplatelet therapy with aspirin and clopidogrel
perhaps indefinitely) is warranted to mitigate the increased
isk of late stent thrombosis despite the significant long-
erm bleeding complications (47) and high costs (46).
autions Regarding Trials of
tents or Surgery in LMS Stenosis
he randomized controlled trial (RCT), considered the
ost robust form of evidence-based medicine, is predicated
n the prerequisite of equipoise, defined as substantial
ncertainty regarding the relative benefits and risks of
ompeting treatment options. As the stakes for LMS
tenosis are much higher than for other forms of CAD,
here are 2 schools of thought regarding how justifiable are
he ongoing or proposed RCT of PCI versus CABG given
urrent knowledge.
Proponents argue that PCI already offers tangible short-
erm advantages over CABG as it is less invasive, reduces
ospitalization duration, avoids the disability of surgical
ecovery, and allows patients to subsequently have CABG if
ecessary. As nearly one-third of LMS patients in Europe
nd one-fifth in the U.S. may have already been treated with
ES (13) based only on underpowered, nonrandomized,
nd potentially biased studies, they advocate RCT to settle
hich is the better treatment, rather than allow the current
ighly variable and potentially dangerous clinical practice.
hey maintain that PCI should be prudently constrained
ithin the strictly controlled and monitored environment of
he RCT and argue that such RCT are essential if innova-
ion is not to be stifled, thereby denying individual patients
nd society as a whole potentially better therapies.
In contrast, opponents of such RCT for LMS stenosis
uestion if there is sufficient evidence of equipoise to
arrant these trials. They maintain that the fundamental
aw of such trials is the lack of equipoise between the
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enefit of many years (7–9), and as stenting has no survival
dvantage over medical therapy in stable CAD (48,49), it is
ounterintuitive to believe or expect that it will do so in
MS stenosis. They emphasize that BMS in LMS stenosis
ere, after promising early results, abandoned because of
xcess late mortality and high intervention rates and that as
ES do not improve clinical outcome over BMS in stable
AD (4), it is unlikely they will do so in LMS stenosis.
urthermore, they argue that the notion that “CABG can
lways be performed later” is a false premise with inherent
isks. First, timely crossover to surgery may be precluded
ecause restenosis in this critical lesion is frequently asymp-
omatic and can be abrupt (20,24). Second, observational
tudies of tens of thousands of patients with multivessel
AD have consistently shown that PCI with stents, fol-
owed by crossover to CABG when necessary, resulted in
nferior survival compared with an initial strategy of CABG
2). The opponents of RCT in LMS stenosis believe that
atients should be offered the documented survival benefit
f CABG (because in no other area of medicine would it be
onsidered ethically justifiable to conduct an RCT that
nvolved withholding a therapy with proven and substantial
enefits) and that many appropriately informed patients
ould be unlikely to trade off substantial and long-term
enefits of CABG (especially in an era when the procedural
ortality and morbidity are relatively low) for a much less
ertain outcome with PCI.
Although there are no easy answers to resolve this
ilemma at the current time, the results of the ongoing
YNTAX study should help inform clinical practice and
uide the design of future trials. Ideally, such trials should:
Be vetted through ethics committees and institutional
review boards that are fully informed about the totality of
evidence, including the clear benefits of CABG on
mortality in LMS stenosis and the lack of efficacy of PCI
in any situation in patients with stable CAD;
Be powered adequately to evaluate the clinically relevant
hard end point of mortality and clinically important
differences to avoid a spurious conclusion that the 2
procedures are equivalent;
Appreciate that early mortality and MACE initially
“disadvantage” surgery, as most of these outcome mea-
surements occur in the perioperative period;
Include long-term follow-up (at least 5 years), as benefits
of surgery accrue with time; and
Maintain a registry of potentially eligible patients not
entered in the trials.
Finally, for the results to be generalizable, a broad
ategory of at-risk patients, typical of those encountered
n routine clinical practice, must be included if feasible or
ompletely described and studied in registries if excluded
rom randomization. It is vital that registry analysis
ncludes risk adjustment, is published with the primary
rial report, and includes sufficient patient descriptors to cermit extrapolation of the results in formulating clinical
udgment.
he Need for a Standardized
ultidisciplinary Team Approach
s for any condition where several therapeutic approaches
re possible, a multidisciplinary team is essential to
nsure the highest likelihood that the most balanced
dvice and best treatment option are offered to patients
ith LMS disease. A multidisciplinary team can ensure
hat the patient understands that whereas short-term
utcomes with PCI may appear satisfactory, the results by
year are less favorable and that significant uncertainties
bout its long-term reliability and durability mandate
urveillance angiography, which should be weighed
gainst the proven survival benefits of surgery. However,
his ideal standard of care may be at risk of gradually
eing eroded by an increasing tendency of partisan
nterests to solely decide and instigate treatment, with the
atient often being influenced into making a pre-
rdained “choice.” Framing information in the simplistic
ormat—“we can fix your blockage with this stent or we
an have the surgeon crack your chest”—while implying
hat the 2 treatments are otherwise equally efficacious
ay ensure patient compliance but undermines the con-
ept of informed consent and indeed misinforms patients.
onclusions
he fact that most patients with LMS stenosis have
ifurcation disease and simultaneous multivessel CAD
redicates against likely long-term success with PCI. Con-
equently, in the absence of contraindications to surgery,
ABG should remain the standard of care for most patients
ith LMS stenosis because of its substantial survival advan-
age and freedom from repeat intervention. Percutaneous
oronary intervention may be a reasonable alternative in
hose with isolated LMS stenosis not involving the bifur-
ation or those ineligible for CABG. However, PCI (with
r without stents of any type) has been shown not to
onfer any survival advantage compared with medical
herapy in any category of patients with stable CAD, and
oncerns remain over the risk of stent thrombosis with
ES, particularly when used in “off-label” situations.
espite their inherent limitations, the results of ongoing
rials with randomized and registry cohorts evaluating
ES with CABG should provide evidence-based guid-
nce in selecting the preferred form of treatment for
MS stenosis in the future. Until then, consistent with
CC/AHA (10,11) and European Society of Cardiology
uidelines (12) and as stated by Serruys et al. (19),
CABG should remain the preferred revascularization
reatment in good surgical candidates with left main
oronary artery disease.”
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